<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="560d193b-5be5-4799-adfc-f7b36dddd434"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. <br/>
      <br/>LIVMARLI<sup>®</sup> (maralixibat) oral solution <br/>LIVMARLI<sup>®</sup> (maralixibat) tablets, for oral use<br/>Initial U.S. Approval:  2021</title>
   <effectiveTime value="20250410"/>
   <setId root="64000394-1ef6-4e76-8ba8-11f25ba1b167"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116902386" root="1.3.6.1.4.1.519.1"/>
            <name>Mirum Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c30aa0a9-1af1-4d61-9821-89c36f9d3205"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250410"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-110" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="9.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sucralose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Edetate Disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-110-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210929"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214662" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210929"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-111" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="19"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sucralose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Edetate Disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-111-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240724"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214662" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240724"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-210" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73071MW2KM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DISTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-210-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219485" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MRX;10</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-215" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73071MW2KM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DISTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-215-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219485" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MRX;15</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-220" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73071MW2KM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DISTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-220-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219485" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MRX;20</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-230" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livmarli</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>maralixibat chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V78M04F0XC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>maralixibat chloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="UYB6UOF69L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>maralixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73071MW2KM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DISTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79378-230-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219485" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MRX;30</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_a22e7439-401b-4ca3-87b4-77ce90d0cc79">
               <id root="8455ac38-eb1d-41ef-8d8d-c7bb3786a422"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <table styleCode="Noautorules" width="100%">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>4/2025</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions (<linkHtml href="#S5.4">5.4</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>7/2024</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="effa1548-44f4-437e-a04d-b82113162c71"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). (<linkHtml href="#S1.2">1.2</linkHtml>)<list listType="unordered">
                                 <item>
                                    <caption>o</caption>
                                    <content styleCode="underline">Limitations of Use:</content>
                                    <br/>LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. (<linkHtml href="#S14.2">14.2</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="7acd36cc-70fd-450f-82ce-cde124a48a18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome</title>
                     <text>
                        <paragraph>LIVMARLI<content styleCode="bold">
                              <sup>®</sup>
                           </content> is indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="882ce65e-11b8-432b-94b8-5be02579635d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis </title>
                     <text>
                        <paragraph>LIVMARLI is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                     <component>
                        <section ID="ID_286cee0d-0db5-40bd-8917-ed54685128ab">
                           <id root="a23acdb6-05b7-4cf2-8a5d-2a79fe56cbab"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="underline">Limitations of Use:</content>
                                    <br/>LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250410"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="11912dd6-3870-44d3-8680-5509cfd4db2b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Use LIVMARLI Oral Solution 9.5 mg/mL for treatment of ALGS. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Use LIVMARLI Oral Solution 19 mg/mL for treatment of PFIC. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>LIVMARLI Tablets can be used for treatment of both ALGS and PFIC in patients weighing 25 kg and above who can swallow tablets. (<linkHtml href="#S2.1">2.1</linkHtml>)<br/>
                              <br/>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">ALGS:</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <list listType="unordered">
                                 <item>
                                    <caption>○</caption>The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before a meal in the morning.</item>
                                 <item>
                                    <caption>○</caption>Starting dose is 190 mcg/kg orally once daily,and should be increased to 380 mcg/kg daily after one week, as tolerated and not to exceed a maximum daily dose of 28.5 mg per day for the oral solution and 30 mg per day for the tablets. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">PFIC:</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <list listType="unordered">
                                 <item>
                                    <caption>○</caption>The recommended dosage is 570 mcg/kg twice daily before a meal.</item>
                                 <item>
                                    <caption>○</caption>Starting dose is 285 mcg/kg orally once daily in the morning and should be increased to 285 mcg/kg twice daily, 428 mcg/kg twice daily, and then to 570 mcg/kg twice daily, as tolerated and not to exceed a maximum daily dose of 38 mg per day for the oral solution and 40 mg per day for the tablets. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>See full prescribing information for additional dosage details for LIVMARLI oral solution and tablet formulations. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="1ce2ecb2-7702-4383-9709-1a0f5aca93a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.1	Important Administration Information</content>
                     </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Use LIVMARLI Oral Solution 9.5 mg/mL for treatment of ALGS.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Use LIVMARLI Oral Solution 19 mg/mL for treatment of PFIC.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">The two strengths of LIVMARLI Oral Solution, 9.5 mg/mL and 19 mg/mL, should not be substituted for one another when treating PFIC patients <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                              </content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">LIVMARLI tablets can be used for treatment of both ALGS and PFIC in patients weighing 25 kg and above who can swallow tablets. Select LIVMARLI Oral Solution or LIVMARLI Tablets based on the patient's weight and ability to swallow tablets <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>
                                    <linkHtml href="#S2.3">, 2.3</linkHtml>)].</content>
                              </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0f72cec8-4043-45a7-b7dd-049ef6990ae1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.2	Recommended Dosage for Alagille Syndrome</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Use LIVMARLI Oral Solution <content styleCode="bold">9.5 mg/ mL</content> or LIVMARLI Tablets for the treatment of <content styleCode="bold">ALGS</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before a meal in the morning. Start dosing at 190 mcg/kg administered orally once daily; after one week, increase to 380 mcg/kg once daily, as tolerated. The maximum daily dose should not exceed 28.5 mg (3 mL) per day for LIVMARLI Oral solution and 30 mg per day for LIVMARLI tablets. Refer to the dosage by weight guidelines presented in <linkHtml href="#Table1">Table 1</linkHtml> for LIVMARLI Oral Solution and <linkHtml href="#Table2">Table 2</linkHtml> for LIVMARLI tablets.</content>
                        </paragraph>
                        <table ID="Table1" width="100%">
                           <caption>Table 1: 9.5 mg/mL LIVMARLI Oral Solution for Patients with ALGS: Volume per Dose (mL) by Weight</caption>
                           <col width="21%"/>
                           <col width="31%"/>
                           <col width="32%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Patient Weight<br/>(kg)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Days 1-7<br/>(190 mcg/kg once daily)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Beginning Day 8<br/>(380 mcg/kg once daily)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">9.5 mg/mL Solution (for ALGS)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">Volume per Dose<br/>(mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">5 to 6</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">7 to 9</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.15</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.3</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">10 to 12</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.45</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">13 to 15</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.3</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">16 to 19</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.35</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.7</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">20 to 24</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.45</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.9</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">25 to 29</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">30 to 34</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1.25</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">35 to 39</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.7</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1.5</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">40 to 49</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.9</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1.75</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">50 to 59</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">2.25</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">60 to 69</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1.25</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">2.5</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">70 or higher</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1.5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">3</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="Table2" width="100%">
                           <caption>Table 2: LIVMARLI Tablets for Patients with ALGS: Dosage by Weight*</caption>
                           <col width="21%"/>
                           <col width="31%"/>
                           <col width="32%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <content styleCode="xmChange">*Select the appropriate product based on the patient's weight and ability to swallow tablets.</content>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Patient Weight<br/>(kg)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Days 1 to 7<br/>(190 mcg/kg QD)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Beginning Day 8<br/>(380 mcg/kg QD)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Less than 25</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">Use Oral Solution</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">Use Oral Solution</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">25 to 32</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">10 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">33 to 43</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">15 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">44 to 65</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">10 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">20 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">66 or higher</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">15 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">30 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="92a74e83-a917-4c7d-bb84-18a44f388c0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.3	Recommended Dosage for Progressive Familial Intrahepatic Cholestasis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Use LIVMARLI Oral Solution <content styleCode="bold">19 mg/mL</content> or LIVMARLI Tablets for the treatment of <content styleCode="bold">PFIC</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The two strengths of LIVMARLI, 9.5 mg/mL and 19 mg/mL, should not be substituted for one another when treating PFIC patients. Special attention should be given to the accurate calculation of the dose volume of LIVMARLI. This is especially important for pediatric patients less than 5 years old as LIVMARLI oral solution contains the excipient propylene glycol (364.5 mg/mL) <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#S10">Overdosage (10)</linkHtml>].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage is 570 mcg/kg twice daily 30 minutes before a meal. The starting dose is 285 mcg/kg orally once daily in the morning, and should be increased to 285 mcg/kg twice daily, 428 mcg/kg twice daily, and then to 570 mcg/kg twice daily, as tolerated. The maximum daily dose should not exceed 38 mg (2 mL) per day for LIVMARLI oral solution and 40 mg per day for LIVMARLI tablets. Refer to the dosing by weight guidelines presented in <linkHtml href="#Table3">Table 3</linkHtml> for LIVMARLI oral solution and <linkHtml href="#Table4">Table 4</linkHtml> for LIVMARLI tablets.</content>
                        </paragraph>
                        <table ID="Table3" width="100%">
                           <caption>Table 3: 19 mg/mL LIVMARLI Oral Solution for Patients with PFIC: Volume per Dose (mL) by Weight</caption>
                           <col width="23%"/>
                           <col width="28%"/>
                           <col width="24%"/>
                           <col width="23%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Patient Weight</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">(kg)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">285 mcg/kg</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">(once daily titrated to twice daily)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">428 mcg/kg</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">(twice daily)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">570 mcg/kg</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">(twice daily as tolerated)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">19 mg/mL Solution (for PFIC)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange">Volume per Dose (mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">5</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.15</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">6 to 7</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.15</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">8 </content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.25</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">9</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.15</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.25</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">10 to 12</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.15</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.25</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.3</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">13 to 15</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.2</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.3</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.4</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">16 to 19</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.25</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.4</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.5</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">20 to 24</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.3</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">25 to 29</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.4</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.8</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">30 to 34</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.45</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.7</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.9</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">35 to 39</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.8</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">40 to 49</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.6</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.9</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">50 to 59</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.8</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">60 or higher</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">0.9</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="Table4" width="100%">
                           <caption>Table 4: LIVMARLI Tablets for Patients with PFIC: Dosage by Weight*</caption>
                           <col width="28%"/>
                           <col width="24%"/>
                           <col width="23%"/>
                           <col width="23%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4" valign="top">
                                    <content styleCode="xmChange">*Select the appropriate product based on the patient's weight and ability to swallow tablets.</content>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Patient Weight (kg)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">285 mcg/kg BID</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">428 mcg/kg BID</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">570 mcg/kg BID</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Less than 25</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">Use Oral Solution</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">Use Oral Solution</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">Use Oral Solution</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">25 to 32</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">15 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">33 to 43</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">10 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">15 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">20 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">44 or higher</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">15 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">20 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="xmChange">20 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="c3b0e5c1-f4c6-422f-9fc9-096b08e8e251"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Missed Dose</title>
                     <text>
                        <paragraph>For once daily dosing: If a dose is missed, it should be taken as soon as possible within 12 hours of the time it is usually taken, and the original dosing schedule should be resumed. If a dose is missed by more than 12 hours, the dose can be omitted and the original dosing schedule resumed.</paragraph>
                        <paragraph>For twice daily dosing: If a dose is missed, it should be taken as soon as possible within 6 hours of the time it is usually taken, and the original dosing schedule should be resumed. If a dose is missed by more than 6 hours, the dose can be omitted and the original dosing schedule resumed.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="7a9a9029-ebdd-45b5-8b36-99b971eb5f7e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	Important Administration Instructions</title>
                     <text>
                        <paragraph>Administer LIVMARLI oral solution and tablets 30 minutes before a meal <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>A calibrated measuring device (0.5 mL, 1 mL or 3 mL oral dosing dispenser) for LIVMARLI oral solution will be provided by the pharmacy to measure and deliver the prescribed dose accurately.</paragraph>
                        <paragraph>After opening the LIVMARLI oral solution bottle, store below 30°C (86°F) and discard any remaining LIVMARLI oral solution after 100 days.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="61b9437a-8d09-4d7b-b6b8-fb09ac8daab5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6	Dosage Modification for Management of Adverse Events</title>
                     <text>
                        <paragraph>Establish the baseline pattern of variability of liver tests prior to starting LIVMARLI, so that potential signs of liver injury can be identified. Monitor liver tests (e.g., ALT [alanine aminotransferase], AST [aspartate aminotransferase], TB [total bilirubin]), DB [direct bilirubin], and International Normalized Ratio [INR]) during treatment with LIVMARLI. Reduce the dosage or interrupt LIVMARLI if new onset liver test abnormalities occur. Once the liver test abnormalities either return back to baseline values or stabilize at a new baseline value, consider restarting LIVMARLI at the last tolerated dose, and increase the dose as tolerated. Consider discontinuing LIVMARLI permanently if liver test abnormalities recur or symptoms consistent with clinical hepatitis are observed <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>LIVMARLI has not been studied in patients with hepatic decompensation. Discontinue LIVMARLI permanently if a patient experiences a hepatic decompensation event (e.g., variceal hemorrhage, ascites, hepatic encephalopathy).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_13f32042-ef11-4684-ae14-b1aa14ab83f5">
                     <id root="101a63fc-e353-4582-9dd7-b43016282382"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7	Administration Modification for Drug Interaction </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Bile Acid Binding Resins</content>
                        </paragraph>
                        <paragraph>Administer LIVMARLI at least 4 hours before or 4 hours after administering the bile acid binding resins <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>
                           </content>
                           <content styleCode="italics">] </content>when used concomitantly<content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="8f34fba8-57f5-4bdf-93db-54dd616dca31"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>LIVMARLI Oral solution:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>9.5 mg of maralixibat per mL (for treatment of ALGS) as a clear, colorless to yellow solution.</item>
                     <item>
                        <caption>•</caption>19 mg of maralixibat per mL (for treatment of PFIC) as a clear, colorless to yellow solution.</item>
                  </list>
                  <paragraph>LIVMARLI Tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>10 mg: white to off-white round tablets debossed with MRX on one side, 10 on the other side.</item>
                     <item>
                        <caption>•</caption>15 mg: white to off-white modified oval tablets debossed with MRX on one side, 15 on the other side.</item>
                     <item>
                        <caption>•</caption>20 mg: white to off-white round tablets debossed with MRX on one side, 20 on the other side.</item>
                     <item>
                        <caption>•</caption>30 mg: white to off-white round tablets debossed with MRX on one side, 30 on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Oral solution:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>9.5 mg of maralixibat per mL: treatment of ALGS. (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>19 mg of maralixibat per mL: treatment of PFIC. (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                        <paragraph>Tablets: 10 mg, 15 mg, 20 mg, and 30 mg. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="eab9eace-600d-48d7-ac8e-60001f7153fe"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy) <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy). (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="eef4f8a4-3b1c-45c1-9b1b-bc8b6b4340ae"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hepatotoxicity: Obtain baseline liver tests and monitor patients  frequently for the first 6 to 8 months after starting therapy, and as clinically indicated thereafter during treatment. If liver test abnormalities or signs of clinical hepatitis occur, consider dose reduction or treatment interruption. For persistent or recurrent liver test abnormalities relative to baseline, discontinue LIVMARLI. Monitor patients with compensated cirrhosis frequently. Permanently discontinue LIVMARLI if hepatic decompensation event occurs. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Gastrointestinal Adverse Reactions: Consider reducing the dosage or interrupting LIVMARLI treatment if a patient experiences persistent diarrhea or abdominal pain, or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever. Consider stopping LIVMARLI treatment if diarrhea or abdominal pain persists and no alternate etiology is identified. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Fat-Soluble Vitamin (FSV) Deficiency: Obtain baseline levels and monitor during treatment. Supplement if deficiency is observed. If FSV deficiency persists or worsens despite FSV supplementation, consider discontinuing LIVMARLI treatment. (<linkHtml href="#S5.3">5.3</linkHtml>)<list listType="unordered">
                                 <item>
                                    <caption>o</caption>Fracture: Consider interrupting LIVMARLI treatment and supplement with FSV. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.</item>
                                 <item>
                                    <caption>o</caption>Bleeding: Interrupt treatment with LIVMARLI. Treatment can be restarted if the FSV deficiency is corrected and bleeding has resolved. </item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Risk of Propylene Glycol Toxicity (Pediatric Patients Less Than 5 years of Age): Total daily intake of propylene glycol should be considered for managing the risk of propylene glycol toxicity. Monitor patients for signs of propylene glycol toxicity. Discontinue if toxicity is suspected. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="bfab7906-5b60-4626-a9f0-57c8e7d44f2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Hepatotoxicity </title>
                     <text>
                        <paragraph>LIVMARLI treatment is associated with a potential for drug-induced liver injury.</paragraph>
                        <paragraph>In the PFIC trial, treatment-emergent hepatic decompensation events and elevations of liver tests or worsening of liver tests occurred. Two patients experienced drug-induced liver injury (DILI) attributable to LIVMARLI. Two additional patients experienced DILI in the open-label extension portion of the trial. Of these four patients, one patient required liver transplant and another patient died.</paragraph>
                        <paragraph>In the ALGS trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred. Most abnormalities included elevations in ALT, AST, and/or TB/DB. One patient whose TB was elevated at baseline discontinued LIVMARLI after 28 weeks due to increased TB above baseline. Four patients had ALT increases that led to dose modification (n=1), dose interruption (n=2), or permanent discontinuation (n=2) of LIVMARLI during the long-term, open-label extension period <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Obtain baseline liver tests because some ALGS and PFIC patients have abnormal liver tests at baseline. Monitor patients frequently for the first 6 to 8 months after starting therapy and as clinically indicated thereafter during treatment with LIVMARLI. Monitor for elevations in liver tests, for the development of liver-related adverse reactions, and for physical signs of hepatic decompensation. If liver test abnormalities or signs of clinical hepatitis occur in the absence of other causes, consider dose reduction or treatment interruption.</paragraph>
                        <paragraph>Permanently discontinue LIVMARLI if a patient experiences the following:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>persistent or recurrent liver test abnormalities, or</item>
                           <item>
                              <caption>•</caption>upon rechallenge, signs and symptoms consistent with clinical hepatitis, or</item>
                           <item>
                              <caption>•</caption>a hepatic decompensation event.</item>
                        </list>
                        <paragraph>The safety and effectiveness of LIVMARLI have not been established in patients with decompensated cirrhosis. Monitor patients with compensated cirrhosis frequently and discontinue LIVMARLI if hepatic decompensation occurs. LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="77d3cf50-31ff-4dff-a511-dcc49df39b8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Gastrointestinal Adverse Reactions</title>
                     <text>
                        <paragraph>Diarrhea and abdominal pain were reported as the most common adverse reactions in patients treated with LIVMARLI<content styleCode="italics"> [see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Consider reducing the dosage or interrupting LIVMARLI treatment if a patient experiences persistent diarrhea or abdominal pain, or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever. Consider stopping LIVMARLI treatment if diarrhea or abdominal pain persists and no alternate etiology is identified. Monitor for dehydration due to diarrhea and treat promptly. LIVMARLI was not evaluated in PFIC patients with chronic diarrhea requiring intravenous fluids.</paragraph>
                        <paragraph>When diarrhea or abdominal pain resolves, restart LIVMARLI at the last tolerated dose and increase the dose as tolerated. Consider stopping LIVMARLI treatment if they recur upon re-challenge with LIVMARLI.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="1e68032d-4085-43bb-804b-2cbc96886ed3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Fat Soluble Vitamin (FSV) Deficiency</title>
                     <text>
                        <paragraph>LIVMARLI may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamins A, D, E, and K (measured using INR levels). ALGS and PFIC patients can have FSV deficiency at baseline and are frequently supplemented with FSV.</paragraph>
                        <paragraph>In ALGS patients in Trial 1, treatment-emergent FSV deficiency was reported in 3 (10%) patients during 48 weeks of treatment.</paragraph>
                        <paragraph>In PFIC patients in Trial 2, treatment-emergent FSV deficiency (assessed biochemically) was reported in 13 (28%) of LIVMARLI-treated patients versus 16 (35%) of placebo-treated patients during 26 weeks of treatment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Bone Fracture</content>
                        </paragraph>
                        <paragraph>Treatment-emergent bone fracture events have been observed more frequently with LIVMARLI-treated patients compared to placebo-treated patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. If fracture occurs, consider interrupting LIVMARLI treatment and supplement with FSV. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Bleeding</content>
                        </paragraph>
                        <paragraph>If bleeding occurs, interrupt treatment with LIVMARLI. LIVMARLI can be restarted if FSV deficiency is corrected and bleeding has resolved.</paragraph>
                        <paragraph>Obtain serum FSV levels prior to initiation of LIVMARLI and monitor the levels periodically during treatment, along with any clinical manifestations of FSV deficiency. Supplement with FSV if FSV deficiency is diagnosed. Consider discontinuing LIVMARLI if FSV deficiency persists or worsens despite adequate FSV supplementation.</paragraph>
                        <paragraph>If complications of FSV deficiency occur, such as fracture or bleeding, consider interrupting LIVMARLI treatment and supplement with FSV. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="051098a3-cf9b-4c09-9c87-eedb03064a7b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.4	Risk of Propylene Glycol Toxicity (Pediatric Patients Less Than 5 Years of Age)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">LIVMARLI oral solution contains propylene glycol. Patients less than 5 years of age are at highest risk for propylene glycol toxicity, and a safe level for propylene glycol exposure with repeated administration has not been established for pediatric patients less than 5 years of age. When LIVMARLI oral solution is administered at the dose (380 mcg/kg once daily) for treatment of cholestatic pruritus in patients with ALGS, the exposure to propylene glycol will be 14.6 mg/kg/day. When LIVMARLI oral solution is administered at the dose (570 mcg/kg twice daily) for treatment of cholestatic pruritus in patients with PFIC, the exposure to propylene glycol will be 21.9 mg/kg/day. The total daily intake of propylene glycol from all sources should be considered for managing the risk of propylene glycol toxicity.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients for signs of potential propylene glycol toxicity, including hemolysis, hyperosmolarity with anion gap metabolic acidosis, acute kidney injury, and CNS toxicity. Discontinue LIVMARLI oral solution if propylene glycol toxicity is suspected <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="aa11a2b5-917b-4d72-86b6-2e53502294a6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Gastrointestinal Adverse Reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Fat Soluble Vitamin (FSV) Deficiency <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥5%) are:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>ALGS: diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, and bone fractures. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>PFIC: diarrhea, fat soluble vitamin deficiency, abdominal pain, liver test abnormalities, hematochezia, and bone fractures. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mirum Pharmaceuticals at 1-855-MRM-4YOU or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="9eaec2e3-d743-4795-99c2-e8461fd843fc"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">ALGS:</content>
                           </content>
                        </paragraph>
                        <paragraph>In the Alagille syndrome clinical development program, which includes five clinical studies comprising 86 patients, patients received doses of LIVMARLI up to 760 mcg/kg per day with a median duration of exposure of 32.3 months (range: 0.03 – 60.9 months). In Trial 1, the 4-week placebo control period occurred after 18 weeks of LIVMARLI treatment. In two supportive studies that included long-term open‑label extensions, only 13 weeks of placebo-controlled treatment occurred which evaluated doses lower than 380 mcg/kg/day. The majority of LIVMARLI exposure in the development program occurred without a placebo control in open-label trial extensions.</paragraph>
                        <paragraph>The most common adverse reactions (≥5%) for ALGS patients treated with LIVMARLI are presented in <linkHtml href="#Table5">Table 5</linkHtml> below. Treatment interruptions or dose reductions occurred in 5 (6%) patients due to diarrhea, abdominal pain, or vomiting.</paragraph>
                        <table ID="Table5" cellpadding="0pt" width="100%">
                           <caption>Table 5: Adverse Reactions Occurring in ≥ 5% of Patients Treated with LIVMARLI in the ALGS Clinical Development Program</caption>
                           <col width="44%"/>
                           <col width="21%"/>
                           <col width="22%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">*Terms were defined as:<br/>
                                    <content styleCode="bold">Fat-Soluble Vitamin deficiency includes:</content>  A, D, E, or K deficiency, or INR increase<br/>
                                    <content styleCode="bold">Abdominal Pain includes</content>: abdominal discomfort, abdominal distension, abdominal pain, abdominal pain lower, abdominal pain upper<br/>
                                    <content styleCode="bold">Transaminases increased includes</content>: ALT abnormal, ALT increased, AST abnormal, AST increased<br/>
                                    <content styleCode="bold">Bone Fracture includes:</content> tibia fracture, rib fracture, hand fracture, humerus fracture, pathological fracture, forearm fracture, clavicle fracture<br/>
                                    <sup>1</sup> Exposure adjusted incidence rate for each adverse reaction type was calculated using the first occurrence of this adverse reaction per patient</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">LIVMARLI (n=86)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Any Grade</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Number of events per 100 person‑years<sup>1</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Diarrhea </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>48 (55.8%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>41.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Abdominal pain* </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>46 (53.5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>38.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Vomiting </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>35 (40.7%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>19.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nausea </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7 (8.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Fat-Soluble Vitamin deficiency* </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>22 (25.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Transaminases increased (ALT, AST)* </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>16 (18.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>6.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Bone Fractures*</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>8 (9.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>3.3</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Liver Test Abnormalities</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Increase in Transaminases</content>
                        </paragraph>
                        <paragraph>In a pooled analysis of patients with ALGS (N=86) administered LIVMARLI, increases in hepatic transaminases (ALT) were observed. Seven (8.1%) patients discontinued LIVMARLI due to ALT increases. Three (3.5%) patients had a decrease in dose or interruption of LIVMARLI in response to ALT increases. In the majority of cases, the elevations resolved or improved after discontinuation or dose modification of LIVMARLI. In some cases, the elevations resolved or improved without change in LIVMARLI dosing. Increases to more than three times baseline in ALT occurred in 26% of patients treated with LIVMARLI and increases to more than five times baseline occurred in 3%. AST increases to more than three times baseline occurred in 16% of patients treated with LIVMARLI, and an increase to more than five times baseline occurred in one patient. Elevations in transaminases were asymptomatic and not associated with bilirubin elevations or other laboratory abnormalities.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Increases in Bilirubin</content>
                        </paragraph>
                        <paragraph>Four (4.6%) patients in the pooled analysis experienced bilirubin increases above baseline, and LIVMARLI was subsequently withdrawn in two of these patients, who had elevated bilirubin at baseline.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">PFIC:</content>
                           </content>
                        </paragraph>
                        <paragraph>In Trial 2, which enrolled 93 patients, 47 patients received doses of LIVMARLI up to 570 mcg/kg BID, with a median duration of exposure of 6 months (range: 0.3-6.7 months).</paragraph>
                        <paragraph>The most common adverse reactions (≥5%) for PFIC patients treated with LIVMARLI at a rate greater than placebo are presented in <linkHtml href="#Table6">Table 6</linkHtml> below. Diarrhea was the most frequent adverse reaction; the majority of episodes were mild and transient with a median duration of 5.5 days. Nineteen (40.4%) LIVMARLI-treated subjects had diarrhea greater than or equal to 7 days. Placebo-treated subjects had a median duration of 3 days of diarrhea and two subjects (4.3%) experienced diarrhea with a duration greater than or equal to 7 days. There were no severe events reported. The majority of abdominal pain events were mild based on AE grading, and associated with concurrent diarrhea.</paragraph>
                        <paragraph>One LIVMARLI-treated patient with an event of mild diarrhea discontinued treatment. Treatment interruptions or dose reductions occurred in 3 (6.4%) LIVMARLI-treated patients due to diarrhea or abdominal pain. No placebo-treated subjects discontinued treatment or had dose reductions or interruptions due to diarrhea.</paragraph>
                        <table ID="Table6" cellpadding="0pt" width="100%">
                           <caption>Table 6: Adverse Reactions (any grade) Occurring in ≥5% and at a Rate Greater Than Placebo in Patients Treated with LIVMARLI in the PFIC Trial</caption>
                           <col width="43%"/>
                           <col width="22%"/>
                           <col width="22%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>†</sup>
                                    <content styleCode="underline">Terms were defined as:</content>
                                    <br/>
                                    <content styleCode="bold">Abdominal Pain includes</content>: abdominal pain, abdominal pain upper, abdominal distension<br/>
                                    <content styleCode="bold">Transaminases increased includes</content>: Hypertransaminasaemia, ALT abnormal, ALT increased, AST abnormal, AST increased, Transaminases increased, Hepatic enzyme increased.<br/>
                                    <content styleCode="bold">Bone Fracture includes</content>: upper limb fracture, lower limb fracture, radius fracture, ulna fracture, femur fracture, foot fracture</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(Any Grade)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n=46</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">LIVMARLI</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n=47</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9 (19.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>27 (57.4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Abdominal pain<sup>†</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (15.2%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>13 (27.7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Transaminases increased (ALT or AST)<sup> †</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3 (6.5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (17%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Hematochezia or rectal hemorrhage </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 (2.2%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4 (8.5%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Bone Fractures<sup>†</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>3 (6.4%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>LIVMARLI treatment is associated with a potential for drug-induced liver injury. In PFIC patients in Trial 2, treatment-emergent elevations of liver tests or worsening of liver tests, relative to baseline values, and hepatic decompensation events were observed. Two patients experienced drug-induced liver injury (DILI) attributable to LIVMARLI; one patient received 570 mcg/kg twice daily and the second patient required dose interruption and reduction. Two additional patients experienced DILI in the open-label extension portion of the trial. Of these four patients, one patient required liver transplant and another patient died.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Biliary Complications</content>
                        </paragraph>
                        <paragraph>In the placebo-controlled portion of Trial 2, two LIVMARLI-treated patients developed cholangitis or cholecystitis within 3-weeks of drug discontinuation (after 84 days and 130 days after initiating LIVMARLI treatment, respectively). Four LIVMARLI-treated patients developed cholecystitis or cholangitis in the open-label extension portion of Trial 2; the average time to onset was 281 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Bone Fracture</content>
                        </paragraph>
                        <paragraph>In PFIC patients in Trial 2, treatment-emergent bone fracture events were observed. Three receiving  LIVMARLI experienced bone fractures relative to none in placebo-treated patients. The median time to onset of fractures was 73 days. Two LIVMARLI-treated patients developed bone fractures in the open-label portion of Trial 2, with average time to onset of fracture was 204 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Bleeding</content>
                        </paragraph>
                        <paragraph>In PFIC patients in Trial 2, treatment-emergent events of hematochezia (4 [8.5%] versus 1 [2.2%]), decrease in hemoglobin greater than or equal to 2 grams/dL from baseline (8 [17%] versus 1 [2.2%]), were reported more frequently in LIVMARLI-treated patients relative to placebo-treated patients</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="4c82ef7f-90e6-495f-a863-a04ad5d378a5"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of LIVMARLI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal disorders:</content> hematemesis, liver transplant, post-endoscopy hemorrhage, post-liver biopsy hemorrhage</paragraph>
                        <paragraph>
                           <content styleCode="underline">General disorders and administration site conditions:</content> drug ineffective</paragraph>
                        <paragraph>
                           <content styleCode="underline">Injury, poisoning and procedural complications</content>: off label use</paragraph>
                        <paragraph>
                           <content styleCode="underline">Investigations</content>: gamma-glutamyltransferase increased</paragraph>
                        <paragraph>
                           <content styleCode="underline">Nervous system disorders</content>: intracranial hemorrhage</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="1eb9fda2-fc7e-4b7a-827b-8d4f83d4b782"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Bile Acid Sequestrants: Modify LIVMARLI administration schedule. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="b93336e7-53f4-4b5c-b7fd-bf30a1a470a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effects of Other Drugs on LIVMARLI</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Bile Acid Binding Resins</content>
                        </paragraph>
                        <paragraph>Bile acid binding resins may bind to maralixibat in the gut. Administer LIVMARLI at least 4 hours before or 4 hours after administration of bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="b114a633-9254-43f2-aade-e21ababcb10d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Effects of LIVMARLI on Other Drugs</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">OATP2B1 substrates</content>
                        </paragraph>
                        <paragraph>Maralixibat is an OATP2B1 inhibitor based on in vitro studies. A decrease in the oral absorption of OATP2B1 substrates (e.g., statins) due to OATP2B1 inhibition in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates (e.g. statins) as needed <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="d6d22318-3d6f-44ec-ad32-7df5fa77f46a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="S8.1">
                     <id root="3aa20ad0-b768-4ba2-8c96-d17abac2840a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Maternal use at the recommended clinical dose of LIVMARLI is not expected to result in measurable fetal exposure because systemic absorption following oral administration is low <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> Maralixibat may inhibit the absorption of fat-soluble vitamins <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#clinical_considerations">Clinical Considerations</linkHtml>]</content>. In animal reproduction studies, no developmental effects were observed <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects for ALGS is higher than the general population because ALGS is an autosomal dominant condition. The background risk of miscarriage for ALGS is unknown. The background risk of birth defects and miscarriage for PFIC is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph ID="clinical_considerations">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Maralixibat may inhibit the absorption of fat-soluble vitamins (FSV). Monitor for FSV deficiency and supplement as needed. Increased supplementation of FSVs may be needed during pregnancy <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph ID="data">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>No effects on embryo-fetal development were observed in pregnant rats treated orally with up to 1000 mg/kg/day (approximately 3300 to 12000 times the maximum recommended dose based on AUC [area under the plasma concentration-time curve]) or in pregnant rabbits treated orally with up to 250 mg/kg/day (approximately 1200 to 4700 times the maximum recommended dose based on AUC) during the period of organogenesis. No effects on postnatal development were observed in a pre- and postnatal development study, in which female rats were treated orally with up to 750 mg/kg/day during organogenesis through lactation. Maternal systemic exposure to maralixibat at the maximum dose tested was approximately 2500 to 9400 times the maximum recommended dose based on AUC.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="d64edbcf-fd6b-48c0-a5b2-137513284f6e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>LIVMARLI has low absorption following oral administration, and breastfeeding is not expected to result in exposure of the infant to LIVMARLI at the recommended dose <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. There are no data on the presence of LIVMARLI in human milk, the effects on the breastfed infant, or the effects on milk production. Patients with ALGS or PFIC can have FSV deficiency as part of their disease. Maralixibat may reduce absorption of fat-soluble vitamins <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>. Monitor FSV levels and supplement FSV intake, if FSV deficiency is observed during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother’s need for LIVMARLI and any potential adverse effects on the breastfed child from LIVMARLI or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="5cc0bf3a-bc07-4719-aa12-084f6c5da3ae"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">ALGS</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of LIVMARLI for the treatment of cholestatic pruritus in Alagille syndrome have been established in pediatric patients aged 3 months of age and older.  Use of LIVMARLI in this population is supported by evidence from a study of patients 1 to 15 years of age (N=31) that included 18 weeks of open-label treatment followed by a 4 week placebo-controlled randomized withdrawal period and a subsequent 26-week open-label treatment period.  Additional safety information was obtained from four studies in patients up to 21 years of age (N=55) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Use of LIVMARLI in patients 3 to &lt;12 months of age is supported by an open-label, multicenter study of LIVMARLI which showed a similar safety, tolerability and pharmacokinetic profile to patients with ALGS <content styleCode="underline">&gt;</content>12 months of age.</paragraph>
                        <paragraph>The safety and effectiveness of LIVMARLI have not been established in patients with ALGS less than 3 months of age.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">PFIC</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of LIVMARLI for the treatment of cholestatic pruritus in PFIC have been established in pediatric patients aged 12 months of age and older. Use of LIVMARLI in this population is supported by evidence from Trial 2 in patients 1 to &lt;18 years of age that included 26 weeks of placebo-controlled safety and efficacy data <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>The 19 mg/mL formulation of LIVMARLI should be used in patients with PFIC in order to minimize exposure to excipients, including propylene glycol. Patients less than 5 years of age are at highest risk for propylene glycol toxicity. The total daily intake of propylene glycol from all sources should be considered for managing the risk of propylene glycol toxicity<content styleCode="italics"> [see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of LIVMARLI have not been established in patients with PFIC younger than 12 months of age.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="99b95f49-7680-4d1d-94ca-f8329fa341f7"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of LIVMARLI for the treatment of pruritus in ALGS or PFIC in adult patients, 65 years of age and older, have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6624909a-b6bc-4111-ab13-dfaf09c649ab"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic impairment</title>
                     <text>
                        <paragraph>Clinical studies of LIVMARLI included ALGS or PFIC patients with impaired hepatic function at baseline. The efficacy and safety in ALGS or PFIC patients with clinically significant portal hypertension and in patients with decompensated cirrhosis have not been established. LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="7856faa4-c444-45b5-83f3-9b30591d10d6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Single doses of maralixibat up to 500 mg, approximately 18-fold higher than the recommended dose, have been administered in healthy adults and were tolerated without a meaningful increase in adverse effects when compared to lower doses. If an overdose occurs, discontinue LIVMARLI, monitor the patient for any signs and symptoms and institute general supportive measures if needed.</paragraph>
                  <paragraph>LIVMARLI contains propylene glycol as an excipient. In cases of suspected overdose, monitor for signs of propylene glycol toxicity, including hemolysis, hyperosmolarity with anion gap metabolic acidosis, acute kidney injury, and CNS toxicity. Discontinue LIVMARLI if propylene glycol toxicity is suspected.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="6274469d-a9a8-449e-bbf9-039e27e6e2d9"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>LIVMARLI (maralixibat) is an ileal bile acid transporter (IBAT) inhibitor. Maralixibat is present as a chloride salt with the chemical name 1-[[4-[[4-[(4<content styleCode="italics">R</content>,5<content styleCode="italics">R</content>)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride. The molecular formula of maralixibat chloride is C<sub>40</sub>H<sub>56</sub>ClN<sub>3</sub>O<sub>4</sub>S with a molecular weight of 710.42. It has the following chemical structure:</paragraph>
                  <renderMultiMedia ID="id-737317680" referencedObject="ID_1d1cb478-4a6a-474a-9cf4-8883c36f7969"/>
                  <paragraph>LIVMARLI oral solution is supplied in a multiple-dose bottle containing 9.5 mg of maralixibat per mL (equivalent to 10 mg of maralixibat chloride per mL), or containing 19 mg of maralixibat per mL (equivalent to 20 mg of maralixibat chloride per mL). The oral solution contains the following inactive ingredients: edetate disodium, grape flavor, propylene glycol, purified water, and sucralose. The pH of the oral solution is 3.8 – 4.8.</paragraph>
                  <paragraph>LIVMARLI tablets are available in 10 mg, 15 mg, 20 mg and 30 mg strengths of maralixibat (equivalent to 10.5 mg, 15.8 mg, 21 mg, and 31.6 mg maralixibat chloride, respectively). The tablets contain the following inactive ingredients: crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="ID_1d1cb478-4a6a-474a-9cf4-8883c36f7969">
                     <text>Chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="d824bf08-840e-429d-a40b-c11597e89843"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="S12.1">
                     <id root="758170bb-86ab-4f44-8db9-c5875a83b405"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by which maralixibat improves pruritus in ALGS or PFIC patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="8620f291-4af8-43bb-9f33-2f67c71c8a23"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">ALGS</content>
                           </content>
                        </paragraph>
                        <paragraph>In Trial 1, pediatric patients with ALGS were administered open-label treatment with LIVMARLI 380 mcg/kg once daily for 13 weeks after an initial 5-week dose-escalation period <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. At baseline, serum bile acids were highly variable among patients ranging from 20 to 749 µmol/L and mean (SD) serum bile acid level was 283 (210.6) µmol/L. Serum bile acid levels decreased from baseline in the majority of patients as early as at Week 12 and the reduction in serum bile acids was generally maintained for the treatment period.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">PFIC</content>
                           </content>
                        </paragraph>
                        <paragraph>In Trial 2, pediatric patients with PFIC were administered LIVMARLI 570 mcg/kg or placebo twice daily for up to 22 weeks after an initial 4–6-week dose escalation period <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. At baseline, serum bile acids concentrations were highly variable among patients ranging from 4 to 504 µmol/L and mean (SD) serum bile acid level was 253 (136) µmol/L. Serum bile acid concentrations decreased from baseline in the majority of patients as early as at Week 2; while the concentrations fluctuated, the reduction in serum bile acids was generally maintained for the treatment period.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="ba79a4ed-6fb9-43a1-9774-8516908e19b3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Because of the low systemic absorption of maralixibat, pharmacokinetic parameters cannot be reliably calculated at the recommended doses. Concentrations of maralixibat in the pediatric ALGS  and PFIC patients were below the limit of quantification (0.25 ng/mL) in the majority of plasma samples.</paragraph>
                        <paragraph>Following single dose administration of maralixibat oral solution in healthy adults at doses ranging from 1 mg to 500 mg, plasma concentrations of maralixibat were below the limit of quantification (0.25 ng/mL) at doses less than 20 mg and PK parameters could not be reliably estimated.</paragraph>
                        <paragraph>Following single dose administration of 30 mg maralixibat oral solution under fasted condition, median Tmax was 0.75 hour and mean (SD) Cmax and AUClast were 1.65 (1.10) ng/mL and 3.43 (2.13) ng·h/mL, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Maralixibat is minimally absorbed and plasma concentrations are often below the limit of quantification (0.25 ng/mL) after single or multiple doses at recommended doses.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Oral Solution</content>: Following a single oral administration of maralixibat 30, 45, and 100 mg liquid formulation under fasted condition, AUClast and Cmax increased in a dose-dependent manner with increase of 4.6-and 2.4-fold, respectively, following a 3.3-fold dose increase from 30 to 100 mg.</paragraph>
                        <paragraph>No accumulation of maralixibat was observed following repeated oral administration of maralixibat in healthy adults at doses up to 100 mg once-daily.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tablet: </content>After a single 100 mg dose of maralixibat tablet under fasted condition, mean (SD) AUCinf and Cmax were 13.2 (8.2) ng·h/mL and 3.0 (2.2) ng/mL, respectively. Following a single dose of maralixibat oral solution (99.75 mg) under the same conditions, mean (SD) AUCinf and Cmax were 18.4 (13.2) ng·h/mL and 4.3 (2.7) ng/mL, respectively. Given the local site of action of maralixibat, the slightly lower exposure afforded by the tablet compared to the oral solution is not clinically meaningful.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Effect of Food</content>
                        </paragraph>
                        <paragraph>Concomitant administration of a high-fat meal with a single dose of maralixibat oral solution decreased both the rate and extent of absorption. AUC and Cmax of maralixibat values in the fed state were 64.8% to 85.8% lower relative to oral administration of 30 mg in fasted conditions. The effect of food on the changes of systemic exposures to maralixibat is not clinically significant <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>
                              <linkHtml href="#S2.3">, 2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Maralixibat shows high binding (91%) to human plasma proteins in vitro.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Following a single dose of 30 mg maralixibat oral solution in healthy adults, the mean half-life (t<sub>1/2</sub>) was 1.6 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>No maralixibat metabolites have been detected in plasma. Three minor metabolites, accounting for &lt;3% of maralixibat-associated fecal radioactivity in total, were identified following administration of [<sup>14</sup>C]maralixibat as an oral solution.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Fecal excretion was found to be the major route of elimination. Following a single dose of 5 mg <sup>14</sup>C-maralixibat as an oral solution, 73% of the dose was excreted in the feces with 0.066% excreted in the urine. 94% of the fecal excretion was as unchanged maralixibat.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of maralixibat were not studied in patients with impaired renal function, including those with end-stage renal disease (ESRD) or those on hemodialysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Other Drugs on Maralixibat</content>
                        </paragraph>
                        <paragraph>Maralixibat is not a substrate of the drug transporters MDR1 (P-gp), BCRP, OATP1B1, OATP1B3, or OATP2B2; therefore, concomitant drug products are not predicted to affect the disposition of maralixibat.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Maralixibat on Other Drugs</content>
                        </paragraph>
                        <paragraph>In vitro, maralixibat did not induce CYP isoforms 1A2, 2B6, or 3A4, nor inhibit CYP isoforms 1A2, 2B6, 2C8, 2C9, 2C19 or  2D6 at clinically relevant concentrations. Maralixibat inhibits CYP3A4 in vitro, however clinically relevant effects on the pharmacokinetics of CYP3A4 substrates are unlikely.  In vitro, maralixibat did not inhibit the transporters MDR1 (P-gp), BCRP, OAT1, OAT3, OATP1B1, OATP1B3, PEPT1, OCT1, OCT2, OCT3, OCTN1, OCTN2, MRP2, MATE1, or MATE2-K at clinically relevant concentrations.</paragraph>
                        <paragraph>Maralixibat inhibits the drug transporter OATP2B1 in vitro, which can potentially result in reduced absorption of drugs that rely on OATP2B1-mediated uptake in the GI tract. In clinical studies coadministration of 4.75 mg maralixibat (once daily in the morning) with daily doses of either simvastatin, or lovastatin in the evening, did not have a clinically relevant effect on the pharmacokinetics of these statins and their metabolites. Coadministration of 4.75 mg maralixibat did not affect pharmacokinetics of atorvastatin.  However, the effect of maralixibat on the pharmacokinetics of OATP2B1 substrates at higher doses has not been evaluated in a clinical study.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="597937f1-ade4-4bb5-ae8d-14e481514676"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>PFIC is a heterogenous disease caused by homozygous or compound heterozygous variants, with different PFIC subtypes occurring in the general population. PFIC1 is caused by variants in the aminophospholipid flippase (ATP8B1) gene, which encodes the Familial Intrahepatic Cholestasis 1 (FIC1) protein, while PFIC2 results from variants in the ABCB11 gene, which encodes the Bile Salt Export Pump (BSEP) protein. PFIC2 is further categorized into BSEP subgroups based on specific variants. The BSEP-1 subgroup includes patients with at least one p.D482G (c.1445A&gt;G) or p.E297G (c.890A&gt;G) variant, BSEP-2 includes patients with at least one missense variant other than p.D482G or p.E297G (non BSEP-1), and BSEP-3 includes patients with variants that are predicted to encode a non-functional protein. PFIC3 is caused by variants in the ABCB4 gene, which encodes multidrug resistance protein 3 (MDR3). PFIC4 is caused by variants in the tight junction protein 2 gene (TJP2), which encodes TJP2. PFIC6 is caused by variants in myosin 5B (MYO5B), which encodes MYO5B. Patients can be clinically diagnosed with PFIC without a known pathogenic variant.</paragraph>
                        <paragraph>PFIC2 is the most common subtype accounting for 37-90% of patients with PFIC. The prevalence of BSEP-1, BSEP-2, and BSEP-3 subgroups are approximately 27.3%, 51.5%, and 21.2%, respectively, based on data from a global consortium characterizing the natural history of severe BSEP deficiency.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="bca91252-22af-41e7-ad92-a4a51e593759"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="S13.1">
                     <id root="81bb783b-597c-4f2b-9723-03cf01da32af"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Maralixibat chloride was not tumorigenic in a 2-year oral carcinogenicity study in rats with administration of up to 100 mg/kg/day (approximately 233 to 870 times the maximum recommended dose based on AUC). In a 26-week oral carcinogenicity study in TgRasH2 mice with doses of up to 25 (males) or 75 (females) mg/kg/day, no drug-related tumors were observed following administration of maralixibat chloride.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Maralixibat chloride was negative in <content styleCode="italics">in vitro</content> (bacterial reverse mutation, chromosomal aberration in mammalian cells) and <content styleCode="italics">in vivo</content> (rat bone marrow micronucleus) assays.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No effects on fertility were observed in female rats treated orally with up to 2000 mg/kg/day or in male rats treated orally with up to 750 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="4a7a0038-fe45-4d88-b7bb-2b4e42582263"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="S14.1">
                     <id root="f7656fc4-e773-4502-b583-ebea276491d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Alagille Syndrome</title>
                     <text>
                        <paragraph>The efficacy of LIVMARLI was assessed in Trial 1 (NCT02160782), which consisted of an 18-week open-label treatment period; a 4-week randomized, double-blind, placebo-controlled drug-withdrawal period; a subsequent 26-week open-label treatment period; and a long-term open-label extension period.</paragraph>
                        <paragraph>Thirty-one pediatric ALGS patients with cholestasis and pruritus were enrolled, with 90.3% of patients receiving at least one medication to treat pruritus at study entry. All patients had JAGGED1 mutation. Patients were administered open-label treatment with LIVMARLI 380 mcg/kg once daily for 13 weeks after an initial 5-week dose-escalation period; two patients discontinued treatment during this first 18 weeks of open-label treatment. The 29 patients who completed the open-label treatment phase were then randomized to continue treatment with LIVMARLI or receive matching placebo during the 4-week drug withdrawal period at Weeks 19-22 (n=16 placebo, n=13 LIVMARLI). All 29 patients completed the randomized, blinded drug withdrawal period; subsequently, patients received open-label LIVMARLI at 380 mcg/kg once daily for an additional 26 weeks.</paragraph>
                        <paragraph>Randomized patients had a median age of 5 years (range: 1 to 15 years) and 66% were male. The baseline mean (standard deviation [SD]) of liver test parameters were as follows: serum bile acid levels 280 (213) µmol/L, AST 158 (68) U/L, ALT 179 (112) U/L, Gamma Glutamyl Transferase (GGT) 498 (399) U/L, and TB 5.6 (5.4) mg/dL.</paragraph>
                        <paragraph>Given the patients’ young age, a single-item observer-reported outcome was used to measure patients’ pruritus symptoms as observed by their caregiver twice daily (once in the morning and once in the evening) on the Itch Reported Outcome Instrument (ItchRO[Obs]). Pruritus symptoms were assessed on a 5-point ordinal response scale, with scores ranging from 0 (none observed or reported) to 4 (very severe). Patients were included in Trial 1 if their average pruritus score was greater than 2.0 (moderate) in the 2 weeks prior to baseline.</paragraph>
                        <paragraph>The average of the worst daily ItchRO(Obs) pruritus scores was computed for each week. For randomized patients, the mean (SD) at baseline (pre-treatment) was 3.1 (0.5) and the mean (SD) at Week 18 (pre-randomized withdrawal period) was 1.4 (0.9). On average, patients administered LIVMARLI for 22 weeks maintained pruritus reduction whereas those in the placebo group who were withdrawn from LIVMARLI after Week 18 returned to baseline pruritus scores by Week 22. Results from the placebo-controlled period are presented in <linkHtml href="#Table7">Table 7</linkHtml>. After re-entering the open-label treatment phase, both randomized treatment groups had similar mean pruritus scores by Week 28, the first week placebo patients received the full dosage of LIVMARLI after withdrawal. These observer-rated pruritus results are supported by similar results on patient-rated pruritus in patients 5 years of age and older who were able to self-report their itching severity.</paragraph>
                        <table ID="Table7" width="100%">
                           <caption>Table 7: Weekly Average of Worst Daily ItchRO(Obs) Pruritus Severity Scores in Trial 1</caption>
                           <col width="36%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="28%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4" valign="top">Results based on an analysis of covariance model with treatment group and Week 18 average worst daily pruritus score as covariates</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Maralixibat</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=13)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=16)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Mean Difference</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Week 22, Mean (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.6 (1.1, 2.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3.0 (2.6, 3.5)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Change from Week 18 to Week 22, Mean (95% CI) </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.2 (-0.3, 0.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1.6 (1.2, 2.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>-1.4 (-2.1, -0.8)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="988c8e17-b989-44b4-a102-278ed3282f49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 	Progressive Familial Intrahepatic Cholestasis</title>
                     <text>
                        <paragraph>The efficacy of LIVMARLI was assessed in Trial 2 (NCT03905330), a 26-week randomized, placebo-controlled trial.</paragraph>
                        <paragraph>Efficacy was evaluated in 64 patients with documented molecular diagnosis of PFIC with presence of biallelic known pathogenic variants; this included 31 non-truncated PFIC2 patients (i.e., excluding patients with BSEP3) and 33 patients with PFIC1 (n=13), PFIC3 (n=9), PFIC4 (n=7), or PFIC6 (n=4) <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>. Additional patients with BSEP3 (n=9), prior surgical diversion (n=8), heterozygous subjects (n=2), or no variants associated with cholestasis (n=8) were included for evaluation in a supplemental cohort <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Patients were randomized to receive maralixibat orally 570 mcg/kg (n=33) or placebo (n=31) twice daily. 53% of pediatric patients were females. Most patients were on stable ursodeoxycholic acid (89.1%) or rifampicin (51.6%) therapy at baseline. The baseline mean (standard deviation [SD]) of liver test parameters were as follows: serum bile acid levels 263 (143) μmol/L, AST 113 (82) U/L, ALT 107 (87) U/L, and TB 4.1 (4.1) mg/dL, DB 3.0 (3.1) mg/dL.</paragraph>
                        <paragraph>Given the patients’ young age, a single-item observer-reported outcome was used to measure patients’ pruritus symptoms as observed by their caregiver twice daily (once in the morning and once in the evening) on the Itch Reported Outcome Instrument (ItchRO[Obs]). Pruritus symptoms were assessed on a 5-point ordinal response scale, with scores ranging from 0 (none observed or reported) to 4 (very severe). Patients were included in Trial 2 if their average pruritus score was greater than or equal to 1.5 in the 4 weeks prior to baseline.</paragraph>
                        <paragraph>
                           <linkHtml href="#Table8">Table 8</linkHtml> presents the results of the comparison between LIVMARLI and placebo on the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15–26. For the outcome summarized over Weeks 15-26, the average morning ItchRO(Obs) severity score for each patient was calculated by: (Step 1) averaging the morning scores within a week; (Step 2) averaging 4 weekly morning scores to yield a single 4-week score; and finally (Step 3) averaging the three 4-week average morning scores (Weeks 15-18, Weeks 19-22, Weeks 23-26). The baseline average itching scores for each patient was calculated by averaging the morning ItchRO(Obs) score obtained in Step 2 across the 4 weeks prior to the first dose of the study. Patients treated with LIVMARLI demonstrated greater improvement in pruritus compared with placebo.</paragraph>
                        <table ID="Table8" width="100%">
                           <caption>Table 8: Average Morning ItchRO(Obs) Pruritus Severity Scores in Trial 2</caption>
                           <col width="50%"/>
                           <col width="22%"/>
                           <col width="22%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup>Results based on least squares means from an analysis of a mixed-effect model for repeated measures (MMRM). Model adjusts for treatment group, visit, treatment group-by-visit interaction, baseline 4-week average morning ItchRO(Obs) severity score, baseline score-by-visit interaction, and PFIC type.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Maralixibat</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=33)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=31)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Baseline Mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Change from baseline to Weeks 15-26<sup>a</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Mean (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>-1.8 (-2.2, -1.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>-0.6 (-1.0, -0.2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Mean difference from Placebo (95% CI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>-1.2 (-1.7, -0.7)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>p-value</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>&lt;0.0001</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#Figure1">Figure 1</linkHtml> displays the means (95% confidence intervals) of patients’ average morning ItchRO(Obs) severity scores in each treatment group for each 4-6 week time period.</paragraph>
                        <table ID="Figure1" styleCode="Noautorules" width="100%">
                           <caption>Figure 1. Mean of the Average Morning ItchRO(Obs) Pruritus Severity Scores Over Time in PFIC 1, 2, 3, 4, and 6</caption>
                           <col width="100%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="1" valign="top">Note: Figure 1 presents least squares mean (95% CI) estimates from a mixed model for repeated measures (MMRM) with observed value as the dependent variable and fixed categorical effects of treatment group, time period, treatment-by-time period interaction, and PFIC type.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top">
                                    <renderMultiMedia ID="id1664" referencedObject="MM2"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Although the number of patients with BSEP3 in Trial 2 were limited, improvement in pruritus was not observed in 5 patients with BSEP3 who received LIVMARLI compared to 4 patients with BSEP3 who received placebo for 26 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="livmarli-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="a2edc216-4806-4233-a673-ca7a19e3d0e1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">LIVMARLI Oral Solution</content>
                  </paragraph>
                  <paragraph>LIVMARLI is a clear, colorless to yellow oral solution.</paragraph>
                  <paragraph>For ALGS: 9.5 mg per mL</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Each amber plastic bottle contains LIVMARLI oral solution at a concentration of 9.5 mg per mL.</item>
                     <item>
                        <caption>•</caption>One 30 mL amber plastic bottle: NDC 79378-110-01</item>
                  </list>
                  <paragraph>For PFIC: 19 mg per mL</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Each amber plastic bottle contains LIVMARLI oral solution at a concentration of 19 mg per mL.</item>
                     <item>
                        <caption>•</caption>One 30 mL amber plastic bottle: NDC 79378-111-01</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">LIVMARLI Tablets</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>10 mg are white to off-white round tablets debossed with MRX on one side, 10 on the other side.</item>
                     <item>
                        <caption> </caption>Bottles of 30 tablets: NDC 79378-210-30</item>
                     <item>
                        <caption>•</caption>15 mg are white to off-white modified oval tablets debossed with MRX on one side, 15 on the other side.</item>
                     <item>
                        <caption> </caption>Bottles of 30 tablets: NDC 79378-215-30</item>
                     <item>
                        <caption>•</caption>20 mg are white to off-white round tablets debossed with MRX on one side, 20 on the other side.</item>
                     <item>
                        <caption> </caption>Bottles of 30 tablets: NDC 79378-220-30</item>
                     <item>
                        <caption>•</caption>30 mg are white to off-white round tablets debossed with MRX on one side, 30 on the other side.</item>
                     <item>
                        <caption> </caption>Bottles of 30 tablets: NDC 79378-230-30</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store unopened LIVMARLI oral solution and tablets between 20°C and 25°C (68°F and 77°F), excursion permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Discard any remaining LIVMARLI oral solution 100 days after opening the bottle<content styleCode="italics"> [see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="e8dae324-30a4-4f8c-a4f8-e7a0545568b3"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient or their caregiver(s) to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients or their caregivers(s) to:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Take LIVMARLI 30 minutes prior to a meal once or twice daily as prescribed.</item>
                     <item>
                        <caption>•</caption>For LIVMARLI oral solution, use a calibrated measuring device (0.5 mL, 1 mL or 3 mL oral dispenser) provided by the pharmacist to measure and deliver the prescribed dose accurately <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>,<linkHtml href="#S2.5"> 2.5)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Take LIVMARLI at least 4 hours before or 4 hours after taking a bile acid binding resin (e.g., cholestyramine, colesevelam, or colestipol) <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                     </item>
                     <item>
                        <caption>•</caption>Store the opened LIVMARLI oral solution bottle below 30⁰C (86⁰F). Discard any unused LIVMARLI 100 days after opening the oral solution bottle <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients or their caregiver(s) that liver tests should be obtained before starting LIVMARLI and periodically during LIVMARLI therapy. Inform patients or their caregiver(s) of the risk of hepatotoxicity that could be fatal and that they will need to undergo monitoring for liver injury. Instruct patients or their caregiver(s) to immediately report any signs or symptoms of severe liver injury to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients or their caregiver(s) to notify their healthcare provider if they experience a new onset or worsening of gastrointestinal symptoms (abdominal pain, vomiting, bloody stool, and diarrhea) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Fat Soluble Vitamin (FSV) Deficiency</content>
                  </paragraph>
                  <paragraph>Advise patients or their caregiver(s) that INR (for vitamin K) and serum levels of vitamins A, D, E will be obtained before starting treatment and periodically during treatment to assess for FSV deficiency <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                     </content>
                     <content styleCode="italics">].</content> Inform patients or their caregiver(s) that they may bleed more easily, may bleed longer, or have a bone fracture. Advise patients or their caregiver(s) to call their healthcare provider for any signs or symptoms of bleeding or report any fractures<content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>Mirum Pharmaceuticals, Inc.<br/>989 E. Hillsdale Blvd., Suite 300<br/>Foster City, CA 94404</paragraph>
                  <paragraph>© 2025 Mirum Pharmaceuticals, Inc.<br/>LIVMARLI<sup>®</sup> is a registered trademark of Mirum Pharmaceuticals, Inc.</paragraph>
                  <paragraph>LB00203 / LB00212</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="ID_5ca5a874-728d-4544-8e47-3ddf04a74a05">
               <id root="650743cf-165d-4b14-9bf8-7df36ac05753"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%"/>
                     <col width="26%"/>
                     <col width="26%"/>
                     <col width="22%"/>
                     <col width="23%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION </content>
                                 <br/>
                                 <content styleCode="bold">LIVMARLI<sup>®</sup> (liv-MAR-lee) </content>
                                 <br/>
                                 <content styleCode="bold">(maralixibat)</content>
                                 <br/>
                                 <content styleCode="bold">oral solution and tablets, for oral use </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is LIVMARLI?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>LIVMARLI is a prescription medicine used to treat: <list listType="unordered">
                                       <item>
                                          <caption>o</caption>cholestatic pruritus (itch) in patients 3 months of age and older with Alagille syndrome (ALGS).</item>
                                       <item>
                                          <caption>o</caption>cholestatic pruritus (itch) in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC).</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.</item>
                                 <item>
                                    <caption>•</caption>It is not known if LIVMARLI is safe and effective in children with ALGS who are under 3 months of age.</item>
                                 <item>
                                    <caption>•</caption>It is not known if LIVMARLI is safe and effective in children with PFIC who are under 12 months of age. </item>
                                 <item>
                                    <caption>•</caption>It is not known if LIVMARLI is safe and effective in adults 65 years of age and older.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking LIVMARLI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if LIVMARLI will harm your unborn baby. Tell your healthcare provider right away if you think that you are pregnant. </item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if LIVMARLI passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you take LIVMARLI.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all medicines that you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should you take LIVMARLI? </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>LIVMARLI is available in oral solution and tablet.</item>
                              </list>
                              <paragraph>Read the Instructions for Use that comes with LIVMARLI for information about the right way to prepare and take LIVMARLI oral solution.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>LIVMARLI oral solution comes in 2 different strengths:<list listType="unordered">
                                       <item>
                                          <caption>o</caption>LIVMARLI oral solution 9.5 mg/mL for use in ALGS</item>
                                       <item>
                                          <caption>o</caption>LIVMARLI oral solution 19 mg/mL for use in PFIC</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>Before you take LIVMARLI oral solution for the first time, talk to your healthcare provider or pharmacist about how to measure the prescribed dose.</item>
                                 <item>
                                    <caption>•</caption>Take LIVMARLI exactly as your healthcare provider tells you to.</item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider may start you on a low dose of LIVMARLI and then increase the dose, especially if you have not taken LIVMARLI.</item>
                                 <item>
                                    <caption>•</caption>Do not change your dose of LIVMARLI unless your healthcare provider tells you to.</item>
                                 <item>
                                    <caption>•</caption>LIVMARLI is taken by mouth, 1 or 2 times each day (if 2 times per day, take in the morning and evening), 30 minutes before a meal. </item>
                                 <item>
                                    <caption>•</caption>If you miss a dose of LIVMARLI and you take LIVMARLI 1-time a day: <list listType="unordered">
                                       <item>
                                          <caption>o</caption>If it is 12 hours or less from the time you usually take LIVMARLI, <content styleCode="bold">take the missed dose as soon as possible</content>.  Then take your next dose at the usual time.</item>
                                       <item>
                                          <caption>o</caption>If it is more than 12 hours from the time you usually take LIVMARLI, <content styleCode="bold">do not take the missed dose</content>. Take your next dose at the usual time.  </item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>If you miss a dose of LIVMARLI and you take LIVMARLI 2-times a day: <list listType="unordered">
                                       <item>
                                          <caption>o</caption>If it is 6 hours or less from the time you usually take LIVMARLI, <content styleCode="bold">take the missed dose as soon as possible</content>.  Then take your next dose at the usual time.</item>
                                       <item>
                                          <caption>o</caption>If it is more than 6 hours from the time you usually take LIVMARLI, <content styleCode="bold">do not take the missed dose</content>. Take your next dose at the usual time.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI. Ask your healthcare provider if you are not sure if you take these medicines.</item>
                                 <item>
                                    <caption>•</caption>If you take too much LIVMARLI, call your healthcare provider or go to the nearest emergency room right away. </item>
                                 <item>
                                    <caption>•</caption>After opening the LIVMARLI oral solution bottle, store below 30°C (86°F). Throw away any remaining LIVMARLI oral solution 100 days after first opening the bottle.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of LIVMARLI? </content>
                                 <br/>
                                 <content styleCode="bold">LIVMARLI can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Liver injury.</content> Changes in certain liver tests are common in patients with ALGS and in patients with PFIC but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment with LIVMARLI to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including:<list listType="unordered">
                                       <item>
                                          <caption>o</caption>nausea or vomiting</item>
                                       <item>
                                          <caption>o</caption>your skin or the white part of your eye turns yellow</item>
                                       <item>
                                          <caption>o</caption>dark or brown urine</item>
                                       <item>
                                          <caption>o</caption>pain on the right side of your stomach (abdomen)</item>
                                       <item>
                                          <caption>o</caption>fullness, bloating, or fluid in your stomach area (ascites)</item>
                                       <item>
                                          <caption>o</caption>loss of appetite </item>
                                       <item>
                                          <caption>o</caption>bleeding or bruising more easily than normal, including vomiting blood</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Stomach and intestinal (gastrointestinal) problems.</content> LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain during treatment. Diarrhea can also cause the loss of too much body fluid (severe dehydration). Your healthcare provider should check your stool for blood and monitor you for too much body fluid loss. <br/>Tell your healthcare provider right away if you have any new or worsening signs or symptoms of stomach and intestinal problems including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>diarrhea</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>more frequent bowel movements than usual</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>stools that are black, tarry, sticky, or have blood or mucous</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>severe stomach-area pain or tenderness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Tell your healthcare provider if you have any signs and symptoms of a loss of too much body fluid including:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>vomiting</item>
                                 <item>
                                    <caption>o</caption>diarrhea</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>urinating less often than usual</item>
                                 <item>
                                    <caption>o</caption>headache</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>dizziness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat.</content> FSV deficiency is common in patients with ALGS and in patients with PFIC but may worsen during treatment with LIVMARLI. Your healthcare provider should do blood tests before starting and during treatment with LIVMARLI. <br/>Other common side effects of FSV deficiency reported during treatment with LIVMARLI were bone fractures and bleeding. Tell your healthcare provider if you have signs or symptoms of bleeding or any fractures.</item>
                              </list>
                              <paragraph>Your healthcare provider may change your dose, or temporarily or permanently stop treatment with LIVMARLI if you have certain side effects.   <br/>These are not all of the possible side effects of LIVMARLI. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store LIVMARLI?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store unopened LIVMARLI oral solution and tablet bottles at room temperature between 68ºF and 77ºF (20ºC and 25°C).</item>
                                 <item>
                                    <caption>•</caption>After opening the LIVMARLI oral solution bottle, store below 30ºC (86ºF). Throw away any remaining LIVMARLI oral solution 100 days after first opening the bottle.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep LIVMARLI and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of LIVMARLI.</content>
                                 <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LIVMARLI for a condition for which it was not prescribed. Do not give LIVMARLI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about LIVMARLI that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in LIVMARLI?</content>
                                 <br/>
                                 <content styleCode="bold">Active ingredients</content>: maralixibat chloride. <br/>
                                 <content styleCode="bold">Oral Solution inactive ingredients</content>: edetate disodium, grape flavor, propylene glycol, purified water, and sucralose.  </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Tablet inactive ingredients</content> crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.</paragraph>
                              <paragraph>Manufactured for: Mirum Pharmaceuticals, Inc., 989 E. Hillsdale Blvd., Suite 300, Foster City, CA 94404</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Botrule " valign="top">
                              <paragraph>For more information, go to www.LIVMARLI.com or call 1-855-MRM-4YOU</paragraph>
                           </td>
                           <td align="right" styleCode="Rrule Botrule " valign="top">
                              <paragraph>LB00203 / LB00212             </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" valign="top">
                              <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph>Revised: April 2025</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="6b43599f-425c-470a-aa66-90ff0287d4f1"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="5%"/>
                     <col width="17%"/>
                     <col width="26%"/>
                     <col width="26%"/>
                     <col width="26%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="5" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                                 <br/>
                                 <content styleCode="bold">LIVMARLI<sup>®</sup> [liv-MAR-lee]</content>
                                 <br/>
                                 <content styleCode="bold">(maralixibat)</content>
                                 <br/>
                                 <content styleCode="bold">oral solution</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>This Instructions for Use contains information on how to take LIVMARLI. Read this Instructions for Use before you start taking LIVMARLI for the first time and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.<br/>
                                 <br/>LIVMARLI is available in two strengths:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>LIVMARLI 9.5 mg/mL is for the treatment of Alagille Syndrome.</item>
                                 <item>
                                    <caption>•</caption>LIVMARLI 19 mg/mL is for the treatment of Progressive Familial Intrahepatic Cholestasis.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Follow your healthcare provider's instructions for the dose of LIVMARLI to give.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Ask your healthcare provider or pharmacist if you have questions about how to prepare or give the prescribed dose of LIVMARLI.<br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Important information about measuring LIVMARLI</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Before you give LIVMARLI for the first time, talk to your healthcare provider or pharmacist about how to correctly measure your prescribed dose.</item>
                                 <item>
                                    <caption>•</caption>You may be given 1 or more dosing dispensers of different sizes as shown in <linkHtml href="#Table1_Instruction_for_use">Table 1</linkHtml> below.  Always use the correct dosing dispenser size provided with LIVMARLI based on your current prescribed dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph ID="Table1_Instruction_for_use">
                                 <content styleCode="bold">Table 1</content>
                              </paragraph>
                           </td>
                           <td valign="top"/>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dose (mL)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dosing dispenser size (mL)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Lrule " valign="top"/>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>0.1 to 0.5</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>0.5</paragraph>
                           </td>
                           <td styleCode="Lrule " valign="top"/>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>0.6 to 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>1</paragraph>
                           </td>
                           <td styleCode="Lrule " valign="top"/>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.25 to 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>3</paragraph>
                           </td>
                           <td styleCode="Lrule " valign="top"/>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Your prescribed dose may change over time. Use the table above to choose the correct dosing dispenser size for your prescribed dose.</item>
                                 <item>
                                    <caption>•</caption>If you do not have the correct dosing dispenser size for your prescribed dose, contact your healthcare provider or pharmacist.</item>
                                 <item>
                                    <caption>•</caption>The dosing dispenser may be used for 100 days if cleaned correctly (see <linkHtml href="#SectionC">Section C</linkHtml>). After 100 days, replace the dosing dispenser with a new one. A new replacement dosing dispenser may be used within the 100 days if necessary.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use a household teaspoon or any other dosing device to measure the dose.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> open more than 1 bottle of LIVMARLI at a time.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> give more than the prescribed dose.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use LIVMARLI after 100 days of first opening the bottle or after the throw away (discard) date listed on the pharmacy label (see <linkHtml href="#SectionD">Section D</linkHtml>).</item>
                                 <item>
                                    <caption>•</caption>When you start a new bottle of LIVMARLI, use a new dosing dispenser.<br/>
                                    <br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Storage information</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store unopened LIVMARLI at room temperature, between 68°F and 77°F (20°C and 25°C).</item>
                                 <item>
                                    <caption>•</caption>After opening the LIVMARLI bottle, store below 86°F (30°C) and throw away (discard) any remaining LIVMARLI after 100 days.</item>
                                 <item>
                                    <caption>•</caption>Store the dosing dispenser in a clean, dry place when not in use.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep LIVMARLI and all medicines out of the reach of children.<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">You will receive</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">LIVMARLI oral solution</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Each package of LIVMARLI contains:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>            <content styleCode="bold">LIVMARLI (9.5 mg/mL or 19 mg/mL):</content>
                                 <br/>
                                 <renderMultiMedia ID="id2066" referencedObject="MM3"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dosing dispensers, provided separately by your pharmacist:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <renderMultiMedia ID="id2074" referencedObject="MM4"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>      <content styleCode="bold">Note:</content> Dosing dispenser sizes shown are for example only.<br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Section A: Prepare the bottle</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>1. Remove the LIVMARLI bottle from the box (See <linkHtml href="#FigureA">Figure A</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Note:</content> The LIVMARLI bottle may not be in a box.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureA">
                                 <renderMultiMedia ID="id2096" referencedObject="MM5"/>
                                 <br/>                    <content styleCode="bold">Figure A</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>2.	 Write the date (bottle open date) on the LIVMARLI bottle (See <linkHtml href="#FigureB">Figure B</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Note:</content> The date of first opening or a throw away (discard) date may already be written on the bottle label by your pharmacist.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureB">
                                 <renderMultiMedia ID="id2111" referencedObject="MM6"/>
                                 <br/>                    <content styleCode="bold">Figure B</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>3. 	Remove the plastic seal from the bottle (See <linkHtml href="#FigureC">Figure C</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Note:</content> Your pharmacist may have already removed the plastic seal from the bottle.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureC">
                                 <renderMultiMedia ID="id2126" referencedObject="MM7"/>
                                 <br/>                        <content styleCode="bold">Figure C<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Section B: Prepare and give LIVMARLI</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 1: Draw the dose</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.1:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Open the bottle by pushing down firmly on the child-resistant cap and turning the cap to the left (counter-clockwise) (See <linkHtml href="#FigureD">Figure D</linkHtml>).<br/>
                                 <content styleCode="bold">Do not</content> throw away the child-resistant cap.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureD">
                                 <renderMultiMedia ID="id2148" referencedObject="MM8"/>
                                 <br/>
                                 <content styleCode="bold">Figure D<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.2:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>If using a new dosing dispenser, remove the dosing dispenser from the wrapper (See <linkHtml href="#FigureE">Figure E</linkHtml>). Throw away (dispose of) the wrapper in household trash.<br/>
                              </paragraph>
                              <paragraph ID="FigureE">
                                 <renderMultiMedia ID="id2158" referencedObject="MM9"/>
                                 <br/>
                                 <content styleCode="bold">Figure E</content>
                              </paragraph>
                              <paragraph>
                                 <br/>If using a used dosing dispenser, make sure the dosing dispenser has been cleaned (See <linkHtml href="#SectionC">Section C</linkHtml>). <br/>If there is a cap on the dosing dispenser, remove it and throw away (dispose of) the cap into the household trash (See <linkHtml href="#FigureF">Figure F</linkHtml>).<br/>
                                 <br/>
                                 <content styleCode="bold">Important:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Make sure you use the correct dosing dispenser size for your prescribed dose (See <linkHtml href="#Table1_Instruction_for_use">Table 1</linkHtml>).</item>
                                 <item>
                                    <caption>•</caption>After 100 days, replace with a new dosing dispenser provided. A new replacement dosing dispenser may be used within the 100 days if necessary.</item>
                                 <item>
                                    <caption>•</caption>Check the dosing dispenser for any damage to the barrel, plunger or tip (See <linkHtml href="#FigureG">Figure G</linkHtml>). If you cannot see the dosage marking or if it becomes hard to move the plunger, replace with a new dosing dispenser.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Note:</content> You can mark the prescribed dose on the dosing dispenser with a thin permanent marker to draw up the prescribed dose more easily.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <paragraph ID="FigureF">
                                 <renderMultiMedia ID="id2178" referencedObject="MM10"/>
                                 <br/>
                                 <content styleCode="bold">Figure F</content>
                              </paragraph>
                           </td>
                           <td colspan="3" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureG">
                                 <renderMultiMedia ID="id2183" referencedObject="MM11"/>
                                 <br/>
                                 <content styleCode="bold">Figure G</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.3:</content> 	Push the plunger down fully to remove air from the dosing dispenser (See <linkHtml href="#FigureH">Figure H</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureH">
                                 <renderMultiMedia ID="id2194" referencedObject="MM12"/>
                                 <br/>
                                 <content styleCode="bold">Figure H<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.4:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Make sure the cap is removed from bottle and insert the tip of the dosing dispenser into the bottle. The tip of the dosing dispenser should fit securely into the hole of the bottle (See <linkHtml href="#FigureI">Figure I</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureI">
                                 <renderMultiMedia ID="id2206" referencedObject="MM13"/>
                                 <br/>
                                 <content styleCode="bold">Figure I<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.5:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Keep the dosing dispenser in place and turn the bottle upside down (See <linkHtml href="#FigureJ">Figure J</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureJ">
                                 <renderMultiMedia ID="id2218" referencedObject="MM14"/>
                                 <br/>
                                 <content styleCode="bold">Figure J<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.6:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Pull back the plunger slowly until the top of the plunger is even with the marking on the barrel of the dosing dispenser for your prescribed dose of LIVMARLI (See <linkHtml href="#FigureK">Figure K</linkHtml>).<br/>See <linkHtml href="#FigureL">Figure L</linkHtml> on how to align the plunger with your prescribed dose.<br/>
                                 <content styleCode="bold">Note:</content> The medicine should appear colorless to light yellow and clear. If it is not, do not use the medicine and contact your pharmacist.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <paragraph ID="FigureK">
                                 <renderMultiMedia ID="id2234" referencedObject="MM15"/>
                                 <br/>
                                 <content styleCode="bold">Figure K</content>
                              </paragraph>
                           </td>
                           <td colspan="3" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureL">
                                 <renderMultiMedia ID="id2239" referencedObject="MM16"/>
                                 <br/>
                                 <content styleCode="bold">Figure L</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Note:</content> Your dose may be different than the dose shown in the figures.<br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.7:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Check the dosing dispenser for air bubbles.  If you see any air bubbles, fully push the plunger so that the medicine flows back into the bottle and withdraw the prescribed dose (See <linkHtml href="#FigureM">Figure M</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureM">
                                 <renderMultiMedia ID="id2255" referencedObject="MM17"/>
                                 <br/>
                                 <content styleCode="bold">Figure M<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.8:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>When you have measured the correct dose, leave the dosing dispenser in the bottle, and turn the bottle right side up (See <linkHtml href="#FigureN">Figure N</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureN">
                                 <renderMultiMedia ID="id2267" referencedObject="MM18"/>
                                 <br/>
                                 <content styleCode="bold">Figure N</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.9:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Carefully remove the dosing dispenser from the bottle by pulling straight up on the barrel of the dosing dispenser (See <linkHtml href="#FigureO">Figure O</linkHtml>).<br/>
                                 <content styleCode="bold">Do not</content> push the dosing dispenser plunger during this step.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureO">
                                 <renderMultiMedia ID="id2281" referencedObject="MM19"/>
                                 <br/>
                                 <content styleCode="bold">Figure O</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
                                    <br/>Step 2: Give the dose</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Note:</content> LIVMARLI should be taken while sitting up or standing.  After taking LIVMARLI wait a few minutes before lying down.<br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.1:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Place</content> the tip of the dosing dispenser against the inside of the cheek (See <linkHtml href="#FigureP">Figure P</linkHtml>) and slowly push the plunger all the way in to give the entire dose of LIVMARLI (See <linkHtml href="#FigureQ">Figure Q</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <paragraph ID="FigureP">
                                 <renderMultiMedia ID="id2301" referencedObject="MM20"/>
                                 <br/>
                                 <content styleCode="bold">Figure P</content>
                              </paragraph>
                           </td>
                           <td colspan="3" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureQ">
                                 <renderMultiMedia ID="id2306" referencedObject="MM21"/>
                                 <br/>
                                 <content styleCode="bold">Figure Q<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.2:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Swallow the dose.<br/> If you are not sure the entire dose was swallowed, do not give another dose. Wait until the next scheduled dose.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.3:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Place</content> the child-resistant cap back on the bottle and turn the cap to the right (clockwise) (See <linkHtml href="#FigureR">Figure R</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureR">
                                 <renderMultiMedia ID="id2324" referencedObject="MM22"/>
                                 <br/>
                                 <content styleCode="bold">Figure R<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph ID="SectionC">
                                 <content styleCode="bold">Section C: Cleaning instructions for the dosing dispenser</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
                                    <br/>Step 1: Rinse dosing dispenser<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.1:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Fill a cup with water (See <linkHtml href="#FigureS">Figure S</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureS">
                                 <renderMultiMedia ID="id2345" referencedObject="MM23"/>
                                 <br/>
                                 <content styleCode="bold">Figure S<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.2:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Clean the dosing dispenser by pulling back on the plunger slowly to fill the dosing dispenser with water from the cup (See <linkHtml href="#FigureT">Figure T</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureT">
                                 <renderMultiMedia ID="id2357" referencedObject="MM24"/>
                                 <br/>
                                 <content styleCode="bold">Figure T<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">1.3:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Over a sink, push the water out of the dosing dispenser (See <linkHtml href="#FigureU">Figure U</linkHtml>). Repeat several times to make sure that all of the LIVMARLI has been removed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureU">
                                 <renderMultiMedia ID="id2369" referencedObject="MM25"/>
                                 <br/>
                                 <content styleCode="bold">Figure U</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 2: Dry the dosing dispenser</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.1:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Remove the plunger from the barrel of the dosing dispenser by pulling the plunger and barrel away from each other (See <linkHtml href="#FigureV">Figure V</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureV">
                                 <renderMultiMedia ID="id2384" referencedObject="MM26"/>
                                 <br/>
                                 <content styleCode="bold">Figure V<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.2:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Shake off excess water (See <linkHtml href="#FigureW">Figure W</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureW">
                                 <renderMultiMedia ID="id2396" referencedObject="MM27"/>
                                 <br/>
                                 <content styleCode="bold">Figure W<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2.3:</content>
                              </paragraph>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph>Place the plunger and barrel on a clean, dry paper towel to air dry.  Store the dosing dispenser in a clean, dry place until your next dose (See <linkHtml href="#FigureX">Figure X</linkHtml>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <paragraph ID="FigureX">
                                 <renderMultiMedia ID="id2408" referencedObject="MM28"/>
                                 <br/>
                                 <content styleCode="bold">Figure X<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>Before you give the next dose, put the dosing dispenser back together by pushing the plunger into the barrel (See <linkHtml href="#FigureY">Figure Y</linkHtml>).</paragraph>
                              <paragraph ID="FigureY">
                                 <renderMultiMedia ID="id2414" referencedObject="MM29"/>
                                 <br/>
                                 <content styleCode="bold">Figure Y<br/>
                                    <br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" colspan="3" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph ID="SectionD">
                                 <content styleCode="bold">Section D: Disposal</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Throw away (dispose of) the bottle of LIVMARLI following the steps below 100 days after first opened or after the throw away (discard) date listed on the pharmacy label, even if there is still medicine in it. <list listType="unordered">
                                       <item>
                                          <caption>1.</caption>Mix medicine with a substance such as dirt, cat litter, or used coffee grounds.</item>
                                       <item>
                                          <caption>2.</caption>Place the mixture in a container such as a sealed plastic bag.</item>
                                       <item>
                                          <caption>3.</caption>Delete all personal information on the prescription label of the empty medicine bottle, then throw away (dispose of) in the household trash or recycle the empty bottle.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>Throw away (dispose of) used dosing dispensers in the household trash.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule " valign="top">
                              <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                           </td>
                           <td align="right" styleCode="Rrule " valign="top">
                              <paragraph>Revised: July 2024</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>LB00203 / LB00212</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure E</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure F</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Figure G</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Figure H</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Figure I</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Figure J</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Figure K</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Figure L</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Figure M</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Figure N</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Figure O</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>Figure P</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM21">
                     <text>Figure Q</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM22">
                     <text>Figure R</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM23">
                     <text>Figure S</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM24">
                     <text>Figure T</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM25">
                     <text>Figure U</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM26">
                     <text>Figure V</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM27">
                     <text>Figure W</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM28">
                     <text>Figure X</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM29">
                     <text>Figure Y</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f713f87d-fb73-4f5f-8b5c-c07022f797e8">
               <id root="a9662c5f-0de2-48a3-809a-af1aacd4a2d9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 9.5 mg/mL Bottle Label</title>
               <text>
                  <paragraph>NDC 79378-110-01<br/>Rx only</paragraph>
                  <paragraph>Livmarli<sup>®</sup>
                     <br/>(maralixibat) oral solution</paragraph>
                  <paragraph>9.5 mg/mL</paragraph>
                  <paragraph>Recommended Dosage:<br/>See prescribing information</paragraph>
                  <paragraph>30 mL</paragraph>
                  <renderMultiMedia ID="id2594" referencedObject="MM30"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM30">
                     <text>PRINCIPAL DISPLAY PANEL - 9.5 mg/mL Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ad18f80d-6fd6-4ec3-a87e-20e53c1b0d8e">
               <id root="ca22d7f4-1d62-4901-8b22-dbb7645c09f5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 19 mg/mL Bottle Label</title>
               <text>
                  <paragraph>NDC 79378-111-01<br/>Rx only</paragraph>
                  <paragraph>Livmarli<sup>®</sup>
                     <br/>(maralixibat) oral solution</paragraph>
                  <paragraph>19 mg/mL</paragraph>
                  <paragraph>For use in Progressive Familial <br/>Intrahepatic Cholestasis</paragraph>
                  <paragraph>30 mL</paragraph>
                  <renderMultiMedia ID="id2617" referencedObject="MM31"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM31">
                     <text>PRINCIPAL DISPLAY PANEL - 19 mg/mL Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7180fac4-59a0-4555-b027-1c935d803b48">
               <id root="8af6bfcd-84fc-46ac-816c-bb0c21fff0ad"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 10 mg Bottle Label </title>
               <text>
                  <paragraph>GTIN: (01) 00379378210305;  NDC 79378-210-30; Rx only<br/>Livmarli (maralixibat) tablets; 10 mg; Recommended Dosage: See prescribing information; 30 tablets;<br/>Each tablet contains 10 mg of maralixibat (equivalent to 10.5 mg of maralixibat chloride).<br/>Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].<br/>Inactive ingredients: crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.<br/>KEEP OUT OF REACH OF CHILDREN.<br/>Manufactured for <br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404 Made in Canada</paragraph>
                  <renderMultiMedia ID="id416527158" referencedObject="AB9F87C7-91A2-4FED-97BA-DB5DB30E4B82"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="AB9F87C7-91A2-4FED-97BA-DB5DB30E4B82">
                     <text>Livmarli tablet 10 mg bottle label 04-2025</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a288bf77-2e29-4e42-8111-aed5d1265fc9">
               <id root="a508ff7a-ce1e-432e-93d3-61993143e19f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 15 mg Bottle Label </title>
               <text>
                  <paragraph>GTIN: (01) 00379378215300;  NDC 79378-215-30; Rx only<br/>Livmarli (maralixibat) tablets; 15 mg; Recommended Dosage: See prescribing information; 30 tablets;<br/>Each tablet contains 15 mg of maralixibat (equivalent to 15.8 mg of maralixibat chloride).<br/>Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].<br/>Inactive ingredients: crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.<br/>KEEP OUT OF REACH OF CHILDREN.<br/>Manufactured for <br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404 Made in Canada</paragraph>
                  <renderMultiMedia ID="id-1809473443" referencedObject="ID_95725bad-cb95-49d0-abda-2a71c578a432"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="ID_95725bad-cb95-49d0-abda-2a71c578a432">
                     <text>Livmarli tablet 15 mg bottle label 04-2025</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_22523161-93cc-4202-8713-2e31baf94dd5">
               <id root="1c6db9c1-238b-4f06-a6b7-a9d6893ae839"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 20 mg Bottle Label </title>
               <text>
                  <paragraph>GTIN: (01) 00379378220304;  NDC 79378-220-30; Rx only<br/>Livmarli (maralixibat) tablets; 20 mg; Recommended Dosage: See prescribing information; 30 tablets;<br/>Each tablet contains 20 mg of maralixibat (equivalent to 21 mg of maralixibat chloride).<br/>Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].<br/>Inactive ingredients: crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.<br/>KEEP OUT OF REACH OF CHILDREN.<br/>Manufactured for <br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404 Made in Canada</paragraph>
                  <renderMultiMedia ID="id270200962" referencedObject="DCAC3776-7947-49E6-8F78-C5A6B3043530"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="DCAC3776-7947-49E6-8F78-C5A6B3043530">
                     <text>Livmarli tablet 20 mg bottle label 04-2025</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b5c10c29-85d8-401d-9afd-fd28d16b4f4b">
               <id root="26856e75-52b3-410b-b022-82eef72ffa6f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 30 mg Bottle Label </title>
               <text>
                  <paragraph>GTIN: (01) 00379378230303;  NDC 79378-230-30; Rx only<br/>Livmarli (maralixibat) tablets; 30 mg; Recommended Dosage: See prescribing information; 30 tablets;<br/>Each tablet contains 30 mg of maralixibat (equivalent to 31.6 mg of maralixibat chloride).<br/>Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].<br/>Inactive ingredients: crospovidone, glyceryl distearate, lactose monohydrate, microcrystalline cellulose, and silicon dioxide.<br/>KEEP OUT OF REACH OF CHILDREN.<br/>Manufactured for <br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404 Made in Canada </paragraph>
                  <renderMultiMedia ID="id1345441300" referencedObject="B9F23D4C-DC98-4869-B7E5-40D0701A0A26"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="B9F23D4C-DC98-4869-B7E5-40D0701A0A26">
                     <text>Livmarli tablet 30 mg bottle label 04-2025</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="livmarli-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>